Abstract

Transcatheter pulmonary valve replacement (TPVR) is the preferred treatment for patients with repaired Tetralogy of Fallot (rTOF) and dysfunctional RV-to-pulmonary artery conduits or surgical bioprosthetic pulmonary valves. With the introduction of the Medtronic Harmony TPV, TPVR candidacy has expanded to include patients with native RV outflow tracts (RVOTs). rTOF patients are at risk for sudden death from ventricular tachycardia (VT), most often using critical RVOT anatomic isthmuses (AI) in the area where TPVs are deployed.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call